Schimke Katrin, Davis Timothy M E
University of Western Australia, School of Medicine and Pharmacology, Fremantle Hospital, PO Box 480, Fremantle, WA 6959, Australia.
Curr Opin Investig Drugs. 2007 Apr;8(4):338-44.
Daiichi Sankyo Inc is developing rivoglitazone, an insulin sensitizer with peroxisome proliferator-activated receptor gamma agonistic activity, for the potential treatment of type 2 diabetes. By March 2006, phase I/III clinical trials were underway in the US and the EU.
第一三共株式会社正在开发利格列酮，一种具有过氧化物酶体增殖物激活受体γ激动活性的胰岛素增敏剂，用于潜在治疗2型糖尿病。截至2006年3月，美国和欧盟正在进行I/III期临床试验。
